A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53

Therapeutic Innovation Australia 2026 Open access

Read full text

Authors: Therapeutic Innovation Australia

DOI: 10.82292/6q6s-2e28

Cited by: 0

Fields of Study & Subjects

Cancer-related Molecular Pathways Amino Acid Enzymes and Metabolism Cancer Hypoxia and Metabolism